Skip to main content
. 2023 Apr 24;91:104562. doi: 10.1016/j.ebiom.2023.104562

Table 3.

EBOV GP-binding antibody GMCs in adult participants at 21 or 28 days post-dose 2, accounting for between-study variations (random intercept model).

Study GMC, EU/mL 95% CI
Overall 5914 2503; 13,976
 EBL2002 7434 6410; 8621
 EBL2004 6910 5939; 8041
 EBL3001 stages 1 and 2 4027 3567; 4516

CI; Confidence interval, EBOV GP; Ebola virus glycoprotein, EU; Enzyme-linked immunosorbent assay unit, GMC; Geometric mean concentration.